knowledge -WSS

knowledge

author：knowledge 2025-10-02 11:08:53 - browse：626

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： The creative science of coining drug names

hotspot

WSS

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Lawmakers grill UnitedHealth CEO on Change cyberattack

Brain technologies pose threats that are all too real, experts warn

Life sciences deals on track to hit lowest point since 2017

Warren pushes Witty on UnitedHealth's control over physicians

knowledge

knowledge

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Affirmative action in medical school literally saved lives

What's changing in Medicare's open enrollment this year?

Activists slam private health insurers over coverage restrictions

Massive project maps cells in human brain in unprecedented detail

In Memoriam: Notable people who died in 2023

Peter Marks talks Operation Warp Speed for Rare Diseases

After affirmative action ruling, medical educators look to 'holistic review'

STAT Readout Newsletter: Today in biotech, life science news

explore

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Life sciences deals on track to hit lowest point since 2017

Life sciences deals on track to hit lowest point since 2017

Empower primary care with adequate payments and technology

Novel spinal cord stimulator treats paralysis without surgery

Can gargling with Listerine treat gonorrhea of the mouth?

entertainment

focus

hotspot

focus